Dr Shari Beth Glynn, DO | |
100 Abbott Park Road, C/o Abbott Laboratories: Ap6d/dept. 058p, Abbott Park, IL 60064-6035 | |
(847) 937-7043 | |
(847) 937-1313 |
Full Name | Dr Shari Beth Glynn |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
Location | 100 Abbott Park Road, Abbott Park, Illinois |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598995870 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 036083768 (Illinois) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Shari Beth Glynn, DO 100 Abbott Park Road, C/o Abbott Laboratories: Ap6d/dept. 058p, Abbott Park, IL 60064-6035 Ph: (847) 937-7043 | Dr Shari Beth Glynn, DO 100 Abbott Park Road, C/o Abbott Laboratories: Ap6d/dept. 058p, Abbott Park, IL 60064-6035 Ph: (847) 937-7043 |
News Archive
New research from the University of Virginia Health System shows that, in cases of Type 1 myotonic muscular dystrophy (DM1), a well known heart protein does several surprising things. DM1 is the most common form of muscular dystrophy in adults and affects approximately 40,000 adults and children in the U.S.
Stronger alcohol policies, including those targeting both excessive drinking and driving while impaired by alcohol, reduce the likelihood of alcohol-related motor vehicle crash deaths, according to a new study from Boston Medical Center and Boston University.
A new analysis by researchers at Massachusetts General Hospital (MGH) offers a novel perspective on the disproportionate impact that COVID-19 has had on people of color, low-income populations, and other structurally disadvantaged groups.
Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.
University of Alabama at Birmingham researchers have proposed a model that resolves a seeming paradox in one of the most intriguing areas of the brain - the dentate gyrus.
› Verified 6 days ago